Is Short-Term ADT Good Enough in High-Risk Prostate Cancer?

Continuing ADT beyond 6 months does not improve outcomes in men with high-risk localized prostate cancer also receiving brachytherapy and external beam radiation therapy, new research suggests.

Related Keywords

Tokyo , Japan , Nihon , Atsunori Yorozu , National Hospital Organization Tokyo Medical Center , International Journal Of Radiation Oncology Biology Physics , Astrazeneca , International Journal , Radiation Oncology Biology , Prostate Carcinoma , Alignant Prostate Neoplasm , Prostate Cancer , Ancer Prostate , Prostatic , Cancer , Alignant Neoplasia , Arcinoma , Metastasis , External Beam Radiation Therapy , Radiation Oncology , Hospitals ,